Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
MOR103 (PerC6 inside) PHASE I
Volgen
bilbo3 schreef:
ja, thuis op pc
zal vanavond (laat) een overzichtje plaatsen
Tnx bilbo3. Indien mogelijk 2008 en 2009 in het overzicht. Zal naar mijn verwachting de aankomende maanden nog wel eens vaker aan de orde komen. Waarschijnlijk dat je eveneens (mis/ge)-bruik met mijn summiere calculaties.
Met dank @ harrysnel: www.iex.nl/forum/topic.asp?forum=228&... MorphoSys and Daiichi Sankyo Forge Alliance to Develop Novel Antibody Therapies against Hospital-Acquired Infections 10/20/2009 at 07:30 AM MorphoSys Secures First Therapeutic Alliance Focused on Infectious Diseases MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment) announced today the formation of a new alliance with DAIICHI SANKYO COMPANY, LIMITED (TSE: 4568) in the discovery and development of therapeutic antibodies for hospital-acquired (nosocomial) infections. Daiichi Sankyo becomes MorphoSys's first collaborator for HuCAL PLATINUM®-based drug discovery in infectious diseases. "This is another landmark deal for MorphoSys and is our first initiative in the infectious disease arena," commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG. "Today's news is proof that MorphoSys can tap new growth opportunities in the therapeutic antibody field on top of the established partnerships the Company has in place. We see lucrative opportunities for our new HuCAL Platinum technology in the infectious disease field, which we intend to exploit within selected partnerships in the years ahead." Under the terms of the agreement, MorphoSys and Daiichi Sankyo will collaboratively apply HuCAL PLATINUM, the latest and most powerful version of MorphoSys's antibody libraries. The companies will jointly apply established as well as novel approaches to generate optimized, fully human therapeutic antibodies against targets associated with nosocomial infections. Daiichi Sankyo will also commit to funding the development of certain infectious disease specific technology at MorphoSys, which will be used to identify the most effective antibody-based drugs. Total payments under the agreement include committed license fees and R&D funding in addition to success-based development milestones. MorphoSys also stands to receive royalties on sales of marketed drugs emerging from the collaboration. There is a large, unmet need for effective, long-lasting drugs against pathogens in difficult to treat nosocomial infections. Current mortality rates in the specific area of focus are reported as 40%-60%, due primarily to resistance to existing antibiotics. The global market for such drugs targeted solely at blood stream infections and hospital acquired pneumonia is estimated to exceed $1 billion. MorphoSys and Daiichi Sankyo started working together in 2006 in a collaboration that has resulted to date in four active therapeutic antibody programs mainly in oncology. The new agreement is built on the strong existing relationship between the partners.www.morphosys.com/en/news_investors/p...
Daiichi Sankyo ook geen onbekende van Crucell:investors.crucell.com/C/132631/PR/200...
flosz schreef:
MorphoSys and Daiichi Sankyo Forge Alliance to Develop Novel Antibody Therapies against Hospital-Acquired Infections
10/20/2009 at 07:30 AM
MorphoSys Secures First Therapeutic Alliance Focused on Infectious Diseases
...
Leuk voor Morphosys, dit is echter WEL directe concurrentie voor Crucell/Medimmune....
maxen schreef:
Leuk voor Morphosys, dit is echter WEL directe concurrentie voor Crucell/Medimmune....
Leiden, The Netherlands, November 2, 2005 – Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) announced today that it has licensed bacterial antigens from ACE BioSciences A/S and the Brigham and Women's Hospital, a teaching hospital of Harvard Medical School, to accelerate its bacterial antibody discovery program. The bacterial surface antigens licensed have been validated for therapeutic efficacy in appropriate animal models for bacterial disease.hugin.info/132631/R/1019118/160183.pdf Gaithersburg, MD, USA and Leiden, The Netherlands - October 15, 2007 - MedImmune and Crucell N.V. (Euronext, NASDAQ: CRXL) announced today that they have entered into an exclusive license and research collaboration to further develop and commercialize one of Crucell's panels of bacterial antibodies primarily for the treatment and prevention of hospital-acquired bacterial infection. In 2005, Crucell announced the initiation of several new antibody discovery programs in the field of hospital-acquired infections.investors.crucell.com/C/132631/PR/200... Kenta, Pseudomonas aeruginosa... Kenta Biotech is an industry spin-off from Berna Biotech Ltd. (a Crucell Company) focusing on the discovery and development of innovative, fully human monoclonal antibodies for the life-saving treatment of patients with serious infectious diseases.www.iex.nl/forum/topic.asp?forum=228&...
Let op de koers van Morphosys!!
Via Binck bank kijken bij Eurpa>Duitsland overig circa 3,5% op 18,27 bij omzet 95000. Volgens mij niet echt vuurwerk
Maar wel een goede overname-kandidaat voor Crucell
jolien54 schreef:
Maar wel een goede overname-kandidaat voor Crucell
Ze hebben gisteren een alliantie bekent gemaakt,vandaar de stijging vandaag.
MorphoSys AG Reports Results for the First Nine Months of 2009 10/28/2009 at 07:00 AM Full Year Guidance Confirmed MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX) today announced its financial results for the nine months ending September 30, 2009 according to International Financial Reporting Standards (IFRS). Group revenues increased by 8 % to EUR 57.6 million (first nine months 2008: EUR 53.3 million) and operating profit was EUR 9.3 million (first nine months 2008: EUR 15.1 million). Net profit amounted to EUR 7.7 million (first nine months 2008: EUR 11.8 million). The main reason for the change in profits was, as planned, increased investment in proprietary drug development, amounting to EUR 11.9 million (first nine months 2008: EUR 3.6 million). MorphoSys's cash position on September 30, 2009 was EUR 139.8 million (December 31, 2008: EUR 137.9 million). The results are broadly in line with the Company's full year guidance Highlights of the Third Quarter of 2009 • Regarding the Company's partnered discovery activities, Bayer Schering Pharma advanced an antibody program into clinical development, triggering a milestone payment to MorphoSys. Bayer Schering Pharma was the third partner in 2009 to file a clinical trial application for a HuCAL-based program, bringing the total number of partnered antibody programs in clinical trials to seven. • The value of MorphoSys's largest alliance with Novartis was further enhanced by Novartis's commitment to the full ten-year term of the strategic alliance signed in December 2007. The achievement of certain predefined improvements in MorphoSys's proprietary technologies was the catalyst for this event. • MorphoSys submitted an application for the authorization of a phase 1b/2a clinical study in patients with active rheumatoid arthritis (RA) for its lead drug MOR103, a fully human HuCAL-derived monoclonal antibody directed against Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF). The Company expects to start the study as planned in the last quarter of 2009. • The appointment of Lisa Rojkjaer as Vice President and Head of Clinical Development further strengthened the Company's development team. • MorphoSys's drug pipeline now comprises 68 therapeutic antibody programs in total, of which eight are currently in clinical development, 28 are in preclinical development and 32 are in the discovery phase. Six of these are MorphoSys's proprietary programs, with MOR103 being the most advanced. • AbD Serotec, MorphoSys's research and diagnostics segment continued to expand into the diagnostics market and signed two new agreements. Spinreact S.A. will incorporate antibodies from AbD Serotec in a series of clinical diagnostic kits. Separately, AbD Serotec will collaborate with FIND diagnostics, Switzerland, to develop new diagnostic tools for poverty related diseases such as malaria and tuberculosis. "Todays results demonstrate MorphoSys remains in top form despite the challenging economic climate in the first nine months of this year," commented Dave Lemus, Chief Financial Officer of MorphoSys AG. "Based on stable and secured cash flows resulting from our partnered discovery business and that of AbD Serotec, we continue to further expand our proprietary product development activities, thereby generating long term value for the Company." www.morphosys.com/en/news_investors/p... Proprietary Development MOR103 In June 2009, MorphoSys has submitted an application to conduct a Phase 1b/2a clinical study in patients with active rheumatoid arthritis and MorphoSys expects clearance in the final quarter of 2009. The trial, which will be conducted in multiple centers in several European countries, is expected to enroll 135 patients in total. Early-stage Pipeline Work on MOR202, MOR205 and MOR203, three cancer programs in pre-clinical and discovery stage, continues as planned and work on MOR104, an early-stage program in inflammation, was initiated in the third quarter of 2009. Proprietary Development This segment involves all activities relating to proprietary therapeutic antibody development. Presently, this includes the Company’s two lead compounds in its proprietary product portfolio, MOR103 and MOR202. Proprietary compounds, once developed to a stage where clinical proof of concept is achieved, can then be outlicensed to third parties. Industry Overview In the third quarter of 2009, antibody-related transactions included Bristol-Myers Squibb’s acquisition of US-based antibody provider Medarex, Inc. for a purchase price of approximately US$ 2.1 billion and Alcon’s acquisition of Swiss-based ESBATech AG, a private biotechnology company focused on single-chain antibody fragment therapeutics for a purchase price of up to US$ 439 million. Significant licensing deals included an alliance in the area of infectious diseases between Johnson & Johnson and Crucell focusing on the discovery, development and commercialization of monoclonal antibodies and vaccines for the treatment and prevention of influenza and other infectious and non-infectious diseases. Additionally, Amgen and GlaxoSmithKline announced a collaboration in which the companies will share commercialization of Amgen's monoclonal antibody Denosumab® for postmenopausal osteoporosis in Europe, Australia, New Zealand and Mexico.www.morphosys.com/uploads/MOR_Q3-2009...
Wat een vreemde laatste allinea, lijkt wel of ze bij die partijen een wit voetje willen halen of de investeerder verleiden om in te stappen omdat ze ook zo'n deal willen maken.
......One point to note here is that we are achieving very high production titres with our partners Crucell and DSM, which supports our positive view of the platform. ____________ Turning to the Proprietary Development segment, here we are progressing according to plan. Regarding MOR103, our anti-GM-CSF antibody, we continue to work through the regulatory process prior to commencing a European phase 1b/2a trial in rheumatoid arthritis patients. We anticipate receiving authorization to start this study soon, at which time we will provide you with details of the trial design. In the meantime, our preclinical studies on potential second and third indications for this drug are delivering promising results. It is no surprise that an antibody targeting an inflammatory mediator such as GM-CSF may have very broad therapeutic applications, and we are confident that there will be opportunities to expand its clinical development beyond our initial focus on RA. This program undoubtedly has blockbuster potential, and we continue to experience strong interest from potential partners in the pharma industry. I want to underscore however, our commitment to taking the program to proof-of-concept in rheumatoid arthritis before looking for a partner. The preclinical development of MOR202 continues to proceed smoothly. One point to note here is that we are achieving very high production titres with our partners Crucell and DSM, which supports our positive view of the platform. Our earlier stage programs also continue. Altogether, we are currently running six proprietary programs – MOR103 and MOR202 as just mentioned, together with three internal discovery programs, two in cancer and one in inflammation As for the future of the overall business, we expect to continue to invest in our proprietary pipeline, while maintaining overall profitability. Along these lines, next year, we plan to have two compounds in clinical trials, MOR103 in a phase 1b/2a trial and MOR202 in a phase 1b trial, which will lead to higher overall expenses in the Proprietary Product segment. More to those numbers when we give our guidance next February at our annual year-end press conference.www.morphosys.com/uploads/091028_Q3-2...
MorphoSys erhält Zulassung für den Start einer klinischen Phase 1b/2a-Studie für das Antikörper-Programm MOR103 09.11.2009 / 07.30 Uhr Paul-Ehrlich-Institut genehmigt klinische Studie in Deutschland an Patienten mit rheumatoider Arthritis Die MorphoSys AG (Frankfurt: MOR; Prime Standard Segment, TecDAX) gab heute bekannt, dass sowohl das deutsche Paul-Ehrlich-Institut (PEI) wie auch die zuständigen Ethik-Kommissionen der Gesellschaft die Genehmigung erteilt haben, eine klinische Studie der Phase 1b/2a an Patienten mit aktiver rheumatoider Arthritis (RA) für ihren am weitesten fortgeschrittenen Wirkstoff MOR103 zu beginnen. Bei dem firmeneigenen Entwicklungsprogramm MOR103 handelt es sich um einen vollständig menschlichen, monoklonalen Antikörper, der gegen das krankheitsrelevante Zielmolekül GM-CSF (Granulozyten-Makrophagen-Kolonie-stimulierender Faktor) gerichtet ist. Die randomisierte, doppelt-verblindet und Placebo-kontrollierte Studie mit einer steigenden Dosis des Antikörpers MOR103 wird in mehreren klinischen Zentren in verschiedenen europäischen Ländern durchgeführt. Sie soll insgesamt rund 135 Patienten einschließen, die trotz vorangegangener Behandlung mit nicht-steroidalen Antirheumatika (NSAIDs), Corticosteroiden, Antirheumatika der DMARD-Klasse (Disease-modifying antirheumatic drugs) und/oder anti-TNF-alpha-Wirkstoffen unter aktiver rheumatoider Arthritis leiden. Die Teilnehmer der Studie erhalten jeweils vier Infusionen des HuCAL-basierten therapeutischen Antikörpers MOR103 in drei von Probandengruppe zu Probandengruppe ansteigenden Dosierungen, oder Placebo. Die Patientenrekrutierung für die Studie wird voraussichtlich im ersten Halbjahr 2011 abgeschlossen sein. Das Unternehmen erwartet die endgültigen Ergebnisse der Studie im ersten Halbjahr 2012. Der primäre Endpunkt der Studie ist es, die Sicherheit und Verträglichkeit des Wirkstoffs MOR103 bei mehrfacher Dosierung von bis zu 1,5 mg/kg im Patienten weiter zu evaluieren. Als weitere Zielvorgaben werden die pharmakokinetischen Eigenschaften des Wirkstoffs untersucht, sowie seine Immunogenität und sein Potenzial, die klinischen Symptome bei RA-Patienten zu verbessern. Hierzu werden die gezeigten Therapieerfolge gemäß der Krankheitskriterien des American College of Rheumatology (ACR) und der European League Against Rheumatism (EULAR28) bewertet sowie Therapiebeurteilungen aus Patientensicht einbezogen. "Wir sind sehr erfreut, die Genehmigung der regulatorischen Behörden und Ethikkommissionen in Deutschland innerhalb kurzer Zeit erhalten zu haben. Dies spricht für die hohe Qualität der von MorphoSys zur Zulassung eingereichten Dokumente und Unterlagen", erklärt Dr. Arndt Schottelius, Entwicklungsvorstand der MorphoSys AG. "Wir werden den Prozess weiter fortsetzen und die Zulassungen der Studienprotokolle auch in den anderen europäischen Ländern, in denen wir Anträge eingereicht haben, anstreben." www.morphosys.com/de/presse_investore...
Meer dan mooi go! Even in dat ander taaltje erbij: MorphoSys Receives Regulatory Approval to Start Phase 1b/2a Clinical Trial for MOR103 Program 11/09/2009 at 07:30 AM Germany's Paul-Ehrlich-Institute Approves Clinical Trial in Rheumatoid Arthritis Patients MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that it has received clearance from Germany's Paul-Ehrlich-Institute as well as a positive opinion from the ethics committees in Germany to commence a Phase 1b/2a human clinical trial in patients with rheumatoid arthritis (RA) of its lead drug MOR103, a fully human monoclonal antibody directed against Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF). In total, the randomized, double-blind, placebo-controlled, dose-escalation trial is expected to enroll 135 patients and will be conducted in multiple centers in several European countries. Patients with active RA despite previous therapy with NSAIDs, corticosteroids, DMARDs and/or anti-TNF-alpha will each receive four infusions of either the HuCAL-derived antibody MOR103 or placebo in three ascending dose cohorts. Enrollment is expected to be completed in the first half of 2011. The final results of the trial are expected in H1 2012. The primary endpoint of the trial is to determine the safety and tolerability of multiple doses of up to 1.5 mg/kg of MOR103 in patients with active RA. Secondary outcome measures will evaluate pharmacokinetics, immunogenicity, and the drug's potential to improve clinical signs and symptoms of RA as measured by ACR and EULAR28 response criteria and patient reported outcomes. "We are pleased to have achieved clearance by the regulatory authorities and ethics committees in Germany in such a short time frame which speaks for the high quality of the application documents provided by MorphoSys," commented Dr. Arndt Schottelius, Chief Development Officer. "We'll continue to work towards finalization of the entire approval process in all European countries where we have filed."
Deutsches Eigenkapitalforum Frankfurt – November 10, 2009 MOR103 Proprietary Inflammation Program MOR103, a fully human HuCAL antibody targeting GM-CSF GM-CSF plays a central role in inflammation and auto-immunity Data support development of GM-CSF mAb therapy in different inflammatory diseases (RA, multiple sclerosis) and lung diseases MOR103 blocks binding of GM-CSF to its receptor with sub-pM affinity Production of clinical material with PER.C6® cell line (Crucell) Clinical Development Primary indication: Rheumatoid arthritis (RA) Commercial opportunity: Anti-TNF therapies such as Enbrel, Remicade, Humira are successful biologic products for treating RA, but fewer than 25% of RA patients are adequately treated Successful completion of phase 1 in healthy volunteers European phase 1b/2a study to start in 2009 Enrollment of 135 patients with active RA despite previous therapy with NSAIDs, corticosteroids, DMARDs and/or anti-TNF-alpha 4 infusions of either MOR103 or placebo in three ascending dose cohorts The primary endpoint of the trial is to determine the safety and tolerability of multiple doses of up to 1.5 mg/kg of MOR103 in patients with active RA Secondary outcome measures will evaluate pharmacokinetics, immunogenicity, and the drug’s potential to improve clinical signs and symptoms of RA Enrollment is expected to be completed in the first half of 2011. The final results of the trial are expected in H1 2012 MOR202 Proprietary Cancer Program MOR202, a fully human HuCAL antibody, targeting CD38, a 45 kDa ectoenzyme heavily over-expressed in 95% of multiple myeloma and some leukemia cell lines Function: Induces cell-killing by ADCC, CDC & apoptosis Primary indication: Multiple myeloma Commercial opportunity 10 % of hematological cancers / 1% of all cancers / 2% of cancer deaths No curative therapies Median survival 24 – 30 months, all patients eventually relapse Outlook 2009: Further evaluation in animal models of multiple myeloma Start of non-clinical safety study to support clinical testing Start of preclinical efficacy studies in second indication Production and release of mAb material for animal safety testing and in preparation for phase 1/2a clinical testing in 2010 © MorphoSys AG Production of clinical material with PER.C6® cell linewww.morphosys.com/uploads/091110_MOR_...
MorphoSys Chief Uses Crisis to Scout for Takeovers, FTD Says By Angela Cullen Dec. 23 (Bloomberg) -- MorphoSys AG Chief Executive Officer Simon Moroney is “actively seeking” potential drug candidates to build up the German biotechnology company’s product pipeline as cash runs out for some of its peers, Financial Times Deutschland reported, citing an interview. Several of these companies have approached MorphoSys about investing in their projects, according to the newspaper. Revenue from a partnership with Novartis AG has given MorphoSys sufficient cashflow to focus on developing its own medicines, the newspaper cited Moroney as saying. www.bloomberg.com/apps/news?pid=20601... ******************** Der Morphosys-Gründer geht davon aus, dass seine Firma wichtige Ergebnisse aus der Phase 2 der klinischen Entwicklung für den "Hoffnungsträger" Mor103 Ende 2011 oder Anfang 2012 vorlegen kann. **************** Morphosys sucht Kaufgelegenheiten Der Augenblick scheint günstig: Das Biotechunternehmen Morphosys versucht, die Schwäche einiger Konkurrenten für Übernahmen zu nutzen. von Annette Ruess, Martinsried Wir sind aktiv auf der Suche nach Produktkandidaten für unsere Pipeline und haben bereits potenzielle Ziele identifiziert", sagt Morphosys-Chef Simon Moroney der FTD. Viele Konkurrenten leiden erheblich unter dem akuten Kapitalmangel in der Branche und sind dementsprechend preiswert zu haben. Zum Teil klopfen finanzschwache Firmen auch bei den Bayern an und bieten ihre Projekte feil. Moroney stellte jedoch klar: "Wir investieren nur Geld in Substanzen, die 100-prozentig zu unserem Portfolio passen." Neben Marktführer Qiagen gehört Morphosys zu den wenigen profitablen Biotechunternehmen in Deutschland, die sich Akquisitionen überhaupt leisten können. Anders als viele Wettbewerber hierzulande hat sich das 1992 in Martinsried bei München gegründete Unternehmen von Beginn an auf das Geschäftsmodell mit Partnerschaften konzentriert. Morphosys entwickelt im Auftrag von großen Pharmaherstellern sogenannte Antikörper; das sind komplizierte Eiweißmoleküle, die gegen Krebs und andere Erkrankungen eingesetzt werden. Derzeit laufen 68 solcher Entwicklungsprogramme. Das Forschungsrisiko liegt bei den Partnern, die Bayern kassieren als Dienstleister Lizenzgebühren und erfolgsabhängige Zahlungen. "Morphosys ist eines der besten deutschen Biotechunternehmen mit einer soliden Struktur", lobt LBBW-Analyst Hanns Frohnmeyer. Das liegt auch an dem Geschäft, das der gebürtige Neuseeländer Moroney 2007 eingefädelt hat: Morphosys vereinbarte mit dem Schweizer Pharmakonzern Novartis eine zehnjährige Forschungsallianz im Wert von mindestens 410 Mio. Euro. Die Kooperation spült jährlich 30 Mio. Euro freien Cashflow in die Kassen von Morphosys. "Der Novartis-Deal erlaubt uns, unseren Fokus jetzt auf die Entwicklung unserer eigenen Medikamente zu legen", sagt Moroney. Derzeit hat das im TecDax notierte Unternehmen zwei Kandidaten in der frühen Forschung: ein Mittel mit der Bezeichnung Mor103 gegen rheumatoide Arthritis und ein Präparat gegen Blutkrebs. Der Morphosys-Gründer geht davon aus, dass seine Firma wichtige Ergebnisse aus der Phase 2 der klinischen Entwicklung für den "Hoffnungsträger" Mor103 Ende 2011 oder Anfang 2012 vorlegen kann. Zum Ausbau der eigenen Forschung und Entwicklung wurde der Posten des Entwicklungsvorstandes geschaffen und mit Arndt Schottelius, einem Ex-Manager des US-Biotech-Pioniers Genentech, besetzt. Zudem wurde im laufenden Jahr die Belegschaft um 60 auf 400 Mitarbeiter aufgestockt. "Um das Programm zu stemmen, haben wir ganz bewusst unsere Forschungs- und Entwicklungskosten auf Kosten des Gewinns hochgefahren", sagt Moroney. Das werde mittelfristig so bleiben. Im laufenden Jahr erhöhte Morphosys diese Ausgaben von 7,7 Mio. Euro auf 18 bis 20 Mio. Euro. Das Ergebnis vor Zinsen und Steuern (Ebit) wird sich deshalb voraussichtlich um bis zu 50 Prozent auf 8 bis 11 Mio. Euro verringern. Der Umsatz soll 80 bis 85 Mio. Euro betragen. Nicht alle Investoren begrüßen die Strategie. Seit Anfang des Jahres hat die Morphosys-Aktie elf Prozent an Wert verloren. Für 2010 plant Morphosys, den Umsatz um 10 bis 15 Prozent zu steigern. Vor allem erhofft Moroney sich aber den Beweis dafür, "dass einer unserer Hucal-Antikörper bei einer bestimmten Krankheit funktioniert". Das wäre ein wichtiges Signal an die Investoren. Neben der Entwicklung von Antikörpern vermarktet Morphosys auch Forschungsantikörper für Kunden aus Wissenschaft und Industrie. Die Sparte, die 25 Prozent des Umsatzes erwirtschaftet, wurde 2005 und 2006 durch Käufe vergrößert. Das Unternehmen möchte sein zweites Standbein vor allem im Diagnosemarkt ausbauen. Moroney, deutscher Biotech-Pionier der ersten Stunde, ist im Gegensatz zu vielen anderen Branchenbeobachtern der Ansicht, dass es in Deutschland trotz zurückliegender Rückschläge bald Erfolge geben werde. Grund sei die hohe Qualität der deutschen Wissenschaftler und Manager in der Branche.www.ftd.de/unternehmen/industrie/:bio...
A Study of the Safety and Preliminary Efficacy of MOR103, a Human Antibody to Granulocyte Macrophage Colony-stimulating Factor (GM-CSF), in Patients With Active Rheumatoid Arthritis This study is ongoing, but not recruiting participants. Estimated Enrollment: 135 Study Start Date: December 2009 Estimated Study Completion Date: July 2011 Estimated Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)clinicaltrials.gov/show/NCT01023256
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
AIRBUS
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia Oyj
Nokia OYJ
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
923,71
+0,04%
EUR/USD
1,0818
-0,67%
FTSE 100
8.245,37
-0,48%
Germany40^
18.547,30
-0,56%
Gold spot
2.293,78
0,00%
NY-Nasdaq Composite
17.133,13
-0,23%
Stijgers
Dalers